---
document_datetime: 2025-09-17 16:12:15
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/roclanda-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: roclanda-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.2328888
conversion_datetime: 2025-12-14 14:52:48.479497
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Roclanda

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                        |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0031/G            | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new | 15/05/2025                          | 14/08/2025                                  | SmPC                             | The SmPC section 6.5 has been updated as follows: 'Roclanda is supplied in clear low density polyethylene bottles (2.5 ml fill in a 4 ml container), low density polyethylene tips with white polypropylene screw caps and anti-tamper seals.' |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | container - Sterile medicinal products and biological/immunological medicinal products B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |             |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10905 /202406 | Periodic Safety Update EU Single assessment - latanoprost / netarsudil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 30/01/2025 | 28/03/2025 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10905/202406. |
| IB/0029/G           | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time                                                                                                                                                                                                                                                                                                                                                              | 17/12/2024 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IA/0030   | B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter                                                                                                                                                                                                                                  | 18/11/2024   | n/a        |                 |                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|------------------|
| IA/0028   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites manufacturer for batch release)                                                                                                                                                                                              | 20/09/2024   | n/a        |                 | (excluding       |
| IB/0026/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a | 02/09/2024   | n/a        |                 | new manufacturer |
| IAIN/0025 | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority                                                                                                                                         | 21/05/2024   | 03/02/2025 | SmPC and PL     |                  |
| IB/0023/G | This was an application for a group of variations. B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation Change in test procedure for the finished                                                                                                                                                                                   | 09/02/2024   | 03/02/2025 | Annex II and PL | B.II.d.2.z -     |

<div style=\"page-break-after: always\"></div>

|                     | product - Other variation B.II.b.z - Change in manufacture of the Finished Product - Other variation A.7 - Administrative change - Deletion of manufacturing sites                                                       |            |            |           |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|-----------------------------------|
| IB/0024             | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                               | 16/01/2024 | n/a        |           |                                   |
| PSUSA/10905 /202306 | Periodic Safety Update EU Single assessment - latanoprost / netarsudil                                                                                                                                                   | 11/01/2024 | n/a        |           | PRAC Recommendation - maintenance |
| N/0022              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                         | 12/12/2023 | 03/02/2025 | Labelling |                                   |
| PSUSA/10905 /202212 | Periodic Safety Update EU Single assessment - latanoprost / netarsudil                                                                                                                                                   | 06/07/2023 | n/a        |           | PRAC Recommendation - maintenance |
| IB/0018             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                   | 05/07/2023 | n/a        |           |                                   |
| IB/0019             | B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product | 14/06/2023 | n/a        |           |                                   |
| II/0011             | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                     | 01/06/2023 | n/a        |           |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                                    |            |            |           |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|-----------------------------------|
| IG/1627             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 29/05/2023 | n/a        |           |                                   |
| IB/0017             | B.II.z - Quality change - Finished product - Other variation                                                                                                                                     | 23/05/2023 | n/a        |           |                                   |
| IB/0015             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                           | 28/03/2023 | n/a        |           |                                   |
| IB/0013             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                             | 20/01/2023 | n/a        |           |                                   |
| PSUSA/10905 /202206 | Periodic Safety Update EU Single assessment - latanoprost / netarsudil                                                                                                                           | 12/01/2023 | n/a        |           | PRAC Recommendation - maintenance |
| N/0012              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                 | 12/12/2022 | 24/03/2023 | Labelling |                                   |
| IAIN/0010           | B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                   | 17/11/2022 | n/a        |           |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0008/G           | This was an application for a group of variations.                                                  | 15/09/2022   | n/a   |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10905 /202112 | Periodic Safety Update EU Single assessment - latanoprost / netarsudil                              | 07/07/2022   | n/a   | PRAC Recommendation - maintenance |
| IB/0007/G           | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) | 27/06/2022   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|         | product formulation - Change that does not affect the product information B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.e.2.d - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition or replacement of a specification parameter as a result of a safety or quality issue   |            |            |             |                                                                               |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------|
| II/0002 | C.I.4, Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study PG324-CS303; this is a prospective, double-masked, randomised, multicentre, active-controlled, parallel-group, 6- month study assessing the safety and ocular hypotensive efficacy of Roclanda compared to bimatoprost + timolol in subjects with elevated intraocular pressure that was insufficiently controlled and/or deemed to be in need of combination IOP- lowering therapy. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to                                                                                     | 02/06/2022 | 24/03/2023 | SmPC and PL | For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                 |            |            |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0006/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                    | 29/03/2022 | 24/03/2023 | SmPC, Labelling and PL |                                   |
| IAIN/0004/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 02/03/2022 | 24/03/2023 | Annex II and PL        |                                   |
| T/0003              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                          | 11/01/2022 | 04/02/2022 | SmPC, Labelling and PL |                                   |
| PSUSA/10905 /202106 | Periodic Safety Update EU Single assessment - latanoprost / netarsudil                                                                                                                                                                                                                                                                                                                       | 13/01/2022 | n/a        |                        | PRAC Recommendation - maintenance |